RFK Jr looks to alter rare disease regulation by fast-tracking drug approvals
During an FDA panel discussion, the US health secretary prioritised easier routes to market for curative therapies.
During an FDA panel discussion, the US health secretary prioritised easier routes to market for curative therapies.
What's Your Reaction?
